Nanoparticle-based Anti-VEGF Treatment For Ocular Neovascularization
Funder
National Health and Medical Research Council
Funding Amount
$576,921.00
Summary
Diseases like AMD and DR are the leading cause for substantial and irreversible vision loss as a direct effect of pathologic ocular neovascularization and have a significant economic impact on individuals, families, health systems and countries. Nowadays, the treatment requires frequent intravitreal injections of anti-VEGF antibody with all the risks of an invasive intraocular procedure. Nanotechonoly-based drug delivery system will provide a less invasive treatment for this kind of disease.